Attached files

file filename
EX-31.2 - EX-31.(I).2 - JUNIPER PHARMACEUTICALS INCjnp-ex312_200.htm
EX-32.2 - EX-32.2 - JUNIPER PHARMACEUTICALS INCjnp-ex322_14.htm
EX-31.1 - EX-31.(I).1 - JUNIPER PHARMACEUTICALS INCjnp-ex311_201.htm
EX-23.2 - EX-23.2 - JUNIPER PHARMACEUTICALS INCjnp-ex232_203.htm
EX-23.1 - EX-23.1 - JUNIPER PHARMACEUTICALS INCjnp-ex231_287.htm
EX-21 - EX-21 - JUNIPER PHARMACEUTICALS INCjnp-ex21_264.htm
10-K - 10-K - JUNIPER PHARMACEUTICALS INCjnp-10k_20171231.htm

Exhibit 32.1

Certification Pursuant to

18 U.S.C. Section 1350

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Juniper Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alicia Secor, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ Alicia Secor

Alicia Secor

President and Chief Executive Officer

(Principal Executive Officer)

Date: March 9, 2018